Koru’s system is designed to allow usage both at home and in clinical settings. Credit: MIND AND I / Shutterstock.

Koru Medical Systems has secured regulatory clearance in Japan for its FreedomEdge infusion system.

The system is now approved for the administration of several drugs, including CSL Behring’s Hizentra subcutaneous immunoglobulin (SCIg), Sobi’s Aspaveli paroxysmal nocturnal haemoglobinuria (PNH), and Takeda Pharmaceutical’s Cuvitru SCIg.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The clearance of the FreedomEdge system in Japan is expected to enhance the quality of care for patients by providing a precise method for administering subcutaneous immunoglobulin and other large-volume therapies.

It is designed to allow usage both at home and in clinical settings.

Designed to be patient-centric, the FreedomEdge system offers customisable features to cater to individual treatment needs.

Its portability and ease of use are expected to empower patients with greater control over their therapy management.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Koru Medical president and CEO Linda Tharby said: “We are very pleased to have received regulatory clearance for the FreedomEdge System in Japan.

“This accomplishment underscores our commitment to advancing healthcare solutions that enhance patients’ lives worldwide and further strengthens Koru’s expansion into international markets.

“With the approval of the FreedomEdge System in Japan, we are proud to broaden access to critical therapies, empowering patients and healthcare providers with a reliable and user-friendly drug delivery platform.”

Last year, Koru submitted a 510(k) premarket notification to the US Food and Drug Administration for its FREEDOM60 syringe infusion system with Hizentra prefilled syringes.